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The effect of three new acyclic adenosine analogs, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine
[(S)-HPMPAJ, 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and (S)-9-(2,3-dihydroxypropyl)adenine [(S)-
DHPA], on Epstein-Barr virus (EBV) replication was studied. Both (S)-HPMPA and PMEA but not (S)-DHPA
effectively inhibited EBV DNA replication in virus-producer P3HR-1 cells and in latently infected Raji cells
superinfected with P3HR-1 virus, as determined by cRNA-DNA hybridization and density gradient centrifu-
gation. The 50% effective doses for inhibiting virus replication were 0.08 and 1.1 ,uM for (S)-HPMPA and
PMEA, respectively. Both drugs were cytostatic but not cytotoxic to the cells at a concentration as high as 100
,uM. These results indicate that (S)-HPMPA and PMEA are potent and selective anti-EBV agents in vitro.
In recent years, we have shown that several nucleoside
analogs selectively inhibit the replication of Epstein-Barr
virus (EBV) (7-10). Most of these drugs are toxic and do not
exhibit a high therapeutic index. A new compound, (S)-9-(3-
hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA],
has recently been shown to have potent and selective
activity against a broad spectrum of human herpesviruses,
such as herpes simplex virus types 1 and 2 (HSV-1 and
HSV-2), varicella-zoster virus, and cytomegalovirus (3).
(S)-HPMPA is also active against seal, monkey, pig, bovine,
and equine herpesviruses; African swine fever virus; vac-
cinia virus; human adenoviruses; and retroviruses (3). Fur-
thermore, thymidine kinase-deficient (TK-) mutants of HSV
and varicella-zoster virus are also susceptible to the drug. In
view of these striking effects against a variety of viruses, we
decided to evaluate the effects of (S)-HPMPA and its close
congener, 9-(2-phosphonylmethoxyethyl)adenine (PMEA),
as well as the parental (S)-9-(2,3-dihydroxypropyl)adenine
[(S)-DHPA] (2), on EBV replication (Fig. 1).
To determine the effects of the drugs on EBV DNA
replication, we used the virus-producing cell line P3HR-1.
Exponentially growing P3HR-1 cells were treated for 14 days
(9) with various concentrations of the drugs in RPMI 1640
medium. The cells were harvested, and EBV genome copy
numbers were determined by complementary RNA-DNA
hybridization with an EBV-specific cRNA probe (9).
Table 1 shows the dose-dependent inhibition of EBV
genome replication by PMEA and (S)-HPMPA. (S)-DHPA
did not show any inhibitory effect at the concentrations
used. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU), a drug
known to be active against EBV replication (7, 10), was
included in the assays as a positive control. EBV genome
copy numbers decreased with increasing concentrations of
PMEA, (S)-HPMPA, and BVdU. The 50% effective dose for
viral inhibition was determined from the semilogarithmic
plot of drug concentrations against viral genome copies per
cell, assuming the residual genome level (-30 copies per
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cell) achieved by an effective drug concentration (100 ,M) as
zero and the viral genome level in the no-drug control as 100
(9). We have shown previously that the residual EBV copy
number of -30 per cell is due to episomal forms, which are
insensitive to antiviral drugs (9). The 50% effective doses
thus obtained were 1.1, 0.08, and 0.06 ,uM for PMEA, (S)-
HPMPA, and BVdU, respectively. The results obtained here
with BVdU are identical to the data reported previously (10).
Interestingly, (S)-DHPA, the parental compound of (S)-
HPMPA, which has been shown to be effective against a
variety of RNA viruses, such as rabies virus, vesicular
stomatitis virus, parainfluenza virus, measles virus, reovi-
ruses, and rotaviruses (2), was not active against EBV
(Table 1).
Since the inhibitory effects of these drugs on EBV could
be the consequence of selective killing of the productive
cells in the P3HR-1 population, we monitored cell growth
and viability during drug treatment. At a drug concentration
of 10 FM, approximately 23 and 34% reductions in cell
number were observed for the PMEA- and (S)-HPMPA-
treated cells (Table 1). At a drug concentration of 100 ,M, a
further reduction (50%) in cell number was observed for the
PMEA-treated cells, compared with an 80% decrease for the
(S)-HPMPA-treated cells; however, the viability of the cells
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FIG. 1. Structures of (S)-DHPA, PMEA, and (S)-HPMPA.
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TABLE 1. Effect of PMEA, (S)-DHPA, (S)-HPMPA, and
BVdU on EBV replication
Drug Cells/ml EBVDrug concn (106)a Viability genome
(ptm) (copies/cell)'
PMEA 0.01 2.7 95 185
0.1 2.6 96 170
1.0 2.8 96 150
10.0 2.1 95 50
100 1.4 92 30
Control 2.8 96 220
(S)-DHPA 0.01 3.1 97 216
0.1 2.8 95 210
1.0 2.6 96 213
10.0 2.3 94 196
100 2.0 96 208
Control 2.8 96 220
(S)-HPMPA 0.01 2.7 96 208
0.1 2.3 93 108
1.0 2.1 93 60
10.0 1.8 95 35
100 0.6 89 NDC
Control 2.8 96 220
BVdU 0.01 2.8 96 214
0.1 2.9 97 101
1.0 2.5 94 78
10.0 2.7 96 56
100 2.4 95 32
Control 2.8 96 220
a Cell density was determined after the cells were grown for 4 days. The
original cell density was 5 x 105/ml.
b Virus-producing cells (P3HR-1) were exposed to various concentrations
of drug for 14 days, and EBV genome copies per cell were determined by
EBV-specific cRNA-DNA hybridization. Results were based upon the aver-
age values for two determinations.
c ND, Not determined.
trations as high as 100 puM. These results indicate that the
drugs are cytostatic but not cytotoxic to P3HR-1 cells.
To assess whether the inhibitory effect of PMEA and
(S)-HPMPA on EBV DNA synthesis is a general phenome-
non and not limited to a particular cell system, we evaluated
the drugs in latently infected Raji cells after superinfection
with P3HR-1 virus (Fig. 2A). The anti-EBV activity of
PMEA (Fig. 2B) and (S)-HPMPA (Fig. 2C) was confirmed.
At concentrations of 5 ,uM, PMEA and (S)-HPMPA com-
pletely inhibited the synthesis of viral DNA in P3HR-1
virus-superinfected Raji cells (cf. Fig. 2B and C with Fig.
2A). Neither PMEA (Fig. 2E) nor (S)-HPMPA (Fig. 2F) had
a significant effect on cell DNA synthesis in Raji cells which
had not been superinfected with the P3HR-1 virus (cf. Fig.
2E and F with Fig. 2D).
The molecular mechanism of inhibition ofEBV replication
by PMEA and (S)-HPMPA remains to be established. The
inhibition of EBV DNA replication at a drug concentration
that is not cytotoxic to the cells suggests that a virus-specific
function is affected. Studies wikh a number of nucleoside
analogs have clearly indicated that the initial phosphoryla-
tion which occurs preferentially in virus-infected cells is a
prerequisite for their selective activity against virus replica-
tion (4; for a review, see reference 6). Subsequently, the
nucleotide analogs are further converted by host cellular
kinases to triphosphates which, in turn, act as either inhib-
itors or substrates for the virus-specific DNA polymerase
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FIG. 2. Inhibition of EBV DNA replication by PMEA and (S)-
HPMPA in superinfected Raji cells. The effect of drugs on DNA
synthesis was determined by measuring the incorporation of 32p into
both viral and cellular DNA which were analyzed by cesium
chloride density gradient centrifugation (9). Shown are
superinfected Raji cells without drug (A), with 5 ,.M PMEA (B), and
with 5 ,uM (S)-HPMPA (C); and mock-infected Raji cells without
drug (D), with 5 pM PMEA (E), and with 5 p.M (S)-HPMPA (F).
(7). With PMEA and (S)-HPMPA, virus-specified TK does
not appear to be required for phosphorylation, since both
TK+ and TK- HSV strains and TK+ and TK- varicella-
zoster virus strains are equally susceptible to the drugs (3).
In addition, (S)-HPMPA is active against the DNA polymer-
ase-based HSV-1 mutants PAAr-1 and PAAr-5 (3). Thus, an
alteration in viral TK or DNA polymerase activity does not
necessarily result in resistance to (S)-HPMPA. (S)-HPMPA
may be taken up by the cells in its native form since it cannot
be enzymatically dephosphorylated. Subsequently, the drug
may be converted by cellular kinase(s) to its active form, the
diphosphoryl derivative, which may be targeted at the viral
DNA polymerase.
Our recent studies indicate that several congeners of
(S)-HPMPA and PMEA are quite effective against human
immunodeficiency virus replication in cell cultures (unpub-
lished data). EBV has been suggested as one of the cofactors
which determine whether human immunodeficiency virus
infection leads to acquired immune deficiency syndrome (5).
Since opportunistic virus infections, in particular herpesvi-
rus (e.g., EBV, cytomegalovirus, HSV, and varicella-zoster
virus) infections, are prevalent in acquired immune defi-
ciency syndrome (1, 11), the broad activity of (S)-HPMPA
and its congeners may have an additional benefit if the drugs
come to be used in treatment.
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The MICs of the new antimicrobial agents cefmetazole, cefotetan, and amoxicillin-clauvulanic acid were
compared with the MICs of other antimicrobial agents against anaerobic bacteria from endometrial cultures
from women with pelvic inflammatory disease or endometritis. The activity of cefmetazole was similar to that
of cefoxitin and generally greater than that of cefotetan. Amoxicillin-clavulanic acid was generally more active
than all cephamycins tested.
Several of the newer antimicrobial agents, among them
cefmetazole, cefotetan, and amoxicillin-clavulanic acid, are
being considered for use in the treatment of upper genital
tract soft tissue infections in women. Since a wide variety of
anaerobic bacteria, including many beta-lactamase-produc-
ing Bacteroides spp., are frequently involved in these infec-
tions, it is important that these antimicrobial agents be
effective against such organisms. Reports of in vitro activity
of these agents against clinical isolates of anaerobic bacteria
are limited mainly to reports of activity against the Bacte-
roides fragilis group (1, 3, 8, 10, 11). We determined the
MICs of some of the newer antimicrobial agents (see Table
1) against anaerobic bacteria isolated from endometrial cul-
tures from women with pelvic inflammatory disease or
postpartum endometritis because anaerobic bacteria other
than the B. fragilis group are more commonly isolated from
cultures from such patients. These MICs were compared
with those of other agents commonly used to treat obstetric
and gynecologic infections (see Table 1). Beta-lactamase
production by organisms was also determined.
Endometrial cultures were obtained by using a double-
catheter-enclosed brush as described by Knuppel et al. (5).
The device was inserted through a speculum to the cervical
os, which had been wiped clean with a large sterile swab.
The inner catheter was extended into the endometrial cavity,
and the brush was extended out of the inner catheter. After
the specimen was obtained, the brush and inner catheter
were retracted into the outer catheter before the device was
removed from the patient.
All of the organisms, which were isolated between May
1984 and May 1986, were recovered from infected women
who had not received antimicrobial treatment for at least 2
months. The organisms were identified by using gas-liquid
chromatography and prereduced anaerobically sterilized me-
dia (2). Organisms which had been frozen in 10% skim milk
at -70°C were subcultured at least twice before susceptibil-
ity testing was done.
Standard powders of the antimicrobial agents were sup-
plied by their manufacturers. The amoxicillin-clavulanic acid
mixture was supplied in combined form by Beecham Labo-
ratories, Bristol, Tenn., with the concentration of amoxicil-
lin being twice that of clavulanic acid. The amount of powder
* Corresponding author.
weighed out to make the initial solution was based on the
concentration of amoxicillin.
MICs were determined by the agar dilution method, with
doubling dilutions of the antimicrobial agents incorporated
into brucella agar supplemented with vitamin K and 5%
sheep blood (9). Overnight growth of organisms in supple-
mented thioglycolate broth was adjusted to the turbidity of a
0.5 McFarland standard and inoculated to the agar plates
with a Steers replicator. The plates were read after being
incubated at 35°C in GasPak jars (BBL Microbiology Sys-
tems, Cockeysville, Md.) for 48 h. Control organisms (B.
fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC
29741, and Peptococcus magnus ATCC 29328) were inocu-
lated with each batch of organisms tested, and the MICs
were within control limits for each antibiotic for each batch.
Beta-lactamase production was determined by the Cefi-
nase disk (BBL) method.
Table 1 shows the range of MICs of each antimicrobial
agent for each group of organisms tested and the MICs for 50
and 90% of the organisms. The activity of cefmetazole was
very similar to that of cefoxitin. All but 5 of the 270 isolates
tested were susceptible to .8 ,ug of either antibiotic per ml.
For four isolates of Peptostreptococcus anaerobius, MICs
were equal to 16 ,ug/ml. For one isolate of Bacteroides
distasonis, MICs were equal to 64 pLg/ml. Cefotetan was less
active than cefmetazole or cefoxitin, with MICs for 50 and
90% of the isolates generally 1 to 2 dilutions higher. Nine
isolates of P. anaerobius, in addition to the B. distasonis
isolate, had cefotetan MICs .32 ,ug/ml. Mezlocillin showed
activity greater than or equal to that of the cephamycins
against anaerobic gram-positive cocci and Fusobacterium
spp. and activity somewhat less than that of cefoxitin or
cefmetazole against the Bacteroides spp.
All isolates were susceptible to amoxicillin-clavulanic
acid, imipenem, and metronidazole. One isolate of Pep-
tostreptococcus asaccharolyticus and one isolate of Bacte-
roides bivius were resistant to clindamycin. These isolates
were both from one patient, and nothing in the medical
history of the patient indicated that she had received prior
treatment with clindamycin, erythromycin, tetracycline, or
any other antimicrobial agent.
Organisms which were inhibited by higher concentrations
of the cephamycins and mezlocillin were generally those in
which beta-lactamase production was detected (Table 2).
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